Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
51
datasets available to search
ShareScore release 0.9.0
Dataset results
51 results for “non-muscle-invasive bladder cancer”
A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov study NCT03558503. IPD Sharing: NO. Countries: 2. Publications: 3.
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov study NCT02808143. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
ClinicalTrials.gov study NCT02792192. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
ClinicalTrials.gov study NCT03379909. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
ClinicalTrials.gov study NCT03759496. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer
ClinicalTrials.gov study NCT03664869. IPD Sharing: NO. Countries: 1. Publications: 21.
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov study NCT06889623. IPD Sharing: NO. Countries: 1. Publications: 5.
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
ClinicalTrials.gov study NCT02716961. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)
ClinicalTrials.gov study NCT06767982. IPD Sharing: YES. Countries: 1. Publications: 5.
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
ClinicalTrials.gov study NCT03421236. IPD Sharing: NO. Countries: 1. Publications: 1.
High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer
ClinicalTrials.gov study NCT05290623. IPD Sharing: NO. Countries: 1. Publications: 16.
The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
ClinicalTrials.gov study NCT06245759. IPD Sharing: NO. Countries: 1. Publications: 1.
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov study NCT07180212. IPD Sharing: NO. Countries: 1. Publications: 0.
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
ClinicalTrials.gov study NCT03258593. IPD Sharing: YES. Countries: 1. Publications: 0.
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
ClinicalTrials.gov study NCT00974818. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial
ClinicalTrials.gov study NCT07198451. IPD Sharing: YES. Countries: 0. Publications: 12.
Immune profiles and DNA methylation alterations related to non-muscle-invasive bladder cancer outcomes
GEO Series GSE183920. Homo sapiens. 603 samples. Type: Methylation profiling by genome tiling array.
Expression profiling by RNA-seq for identifying genes associated with prognosis in non-muscle-invasive bladder cancer.
GEO Series GSE163899. Homo sapiens. 32 samples. Type: Expression profiling by high throughput sequencing.
High-frequency recurrence index for predicting multiple recurrences in non-muscle-invasive bladder cancer (Validation cohort)
GEO Series GSE294705. Homo sapiens. 94 samples. Type: Expression profiling by high throughput sequencing.
Data from: Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer
The prognostic value of repeat transurethral resection of bladder tumor (TURBT) in patients with diagnosed high-risk, non-muscle-invasive bladder cancer (NMIBC) was investigated. We retrospectively reviewed the medical records of patients treated from October 2004 to December 2013 at Seoul National University who underwent repeated TURBT within 2–6 weeks after an initial resection. The study enrolled patients who had been diagnosed with NMIBC at both the initial and repeat TURBT; patients with muscle-invasive tumors on repeat TURBT were excluded. We used stepwise multivariate Cox regression models stratified by study to assess the independent effects of the predictive factors and estimated hazard ratios (HRs) from the Cox models. We investigated a total of 198 patients who were diagnosed with high-risk NMIBC. In logistic regression analyses, number of bladder tumors (2–7: OR, 2.319; 8≤: OR, 3.353; p<0.05), initially high tumor grade (OR, 2.435; p = 0.040), and presence of carcinoma in situ lesion (OR, 3.639; p = 0.017) correlated with residual tumor in the repeated-TURBT specimen. T1 stage in repeated-TURBT significantly correlated with recurrence (HR, 1.837; p = 0.010) and progression (HR, 2.806; p = 0.029) in multivariate analysis. The high grades of tumors in repeated-TURBT also significantly correlated with progression but not recurrence in the multivariate analysis (HR 2.152; p = 0.008). In this study, the pathologic findings in repeated-TURBT correlated with recurrence and progression in high-risk NMIBC. Repeated-TURBT is valuable because it can predict the recurrence and progression of high-risk NMIBC in addition to obtaining accurate pathologic findings.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.